tirzepatide effective dose appears to be more than standard care in early type 2 diabetes TIRZEPATIDE (MOUNJARO® / ZEPBOUND®) AND

Limitations and Remaining Questions While semaglutide has shown significant benefits in reducing joint pain among patients with obesity, several important limitations remain: Studies often lack post-treatment follow-up, making it unclear how durable these pain and weight outcomes are once medication is stopped

Moreover, long-lived eat-2(ad1116) mutants, when fed with bacteria expressing dsRNA bec-1 , showed a decrease in life span (Supplemental Figure 6B and Supplemental Figure 11D), as previously reported (29)

Obesity (Silver Spring) 2023;31 Suppl 1:9-21.PubMed 289

Third, comedication use and concurrent medical conditions were only considered at baseline, without accounting for changes over time, which could influence the observed associations